Table 3.
NHIS budget impact for the entire treated population (343 488 patients).
| Total costs (GH¢ undiscounted) | ||||||
|---|---|---|---|---|---|---|
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Total | |
| NI | 5 507 598 | 6 453 082 | 7 102 141 | 7 549 956 | 7 861 999 | |
| TZD | 8 426 749 | 13 312 890 | 13 688 062 | 13 925 951 | 14 067 494 | |
| CCB | 71 468 372 | 135 651 998 | 132 349 908 | 129 102 548 | 125 960 627 | |
| ACEI | 66 093 318 | 124 245 912 | 120 836 360 | 117 496 649 | 114 292 309 | |
| ARB | 48 538 500 | 89 934 993 | 87 600 771 | 85 267 258 | 83 003 255 | |
| BB | 22 496 680 | 39 411 909 | 38 867 829 | 38 203 087 | 37 485 339 | |
| TZD vs NI | 2 919 150 | 6 859 808 | 6 585 921 | 6 375 995 | 6 205 495 | 28 946 370 |
| CCB vs TZD | 63 041 623 | 122 339 108 | 118 661 846 | 115 176 597 | 111 893 132 | 531 112 307 |
ACEi indicates angiotension-converting enzyme inhibitor; ARB, angiotension receptor blocker; BB, beta-blocker; CCB, calcium channel blocker; GH¢, Ghana cedis; NI, no intervention; TZD, thiazide-like diuretic.